U.S. FDA Adds Sunscreen Ingredient Bemotrizinol, Bringing a Rare Update to OTC Sunscreen Regulation

The U.S. Food and Drug Administration (FDA) announced that it has completed a final order adding bemotrizinol as an active ingredient that may be used in U.S. over-the-counter (OTC) sunscreen products. The significance of this decision is not only that one more sunscreen ingredient is available, but that it represents a substantive update rarely seen in U.S. OTC sunscreen regulation in many years.

According to information released by the FDA, bemotrizinol can provide UVA and UVB protection and has low systemic absorption. In other words, regulators consider that it has a sufficient data basis, in terms of both sunscreen efficacy and human exposure risk, to be included on the permitted list. However, publicly available summary information is currently limited, and observers will still need to wait for actual product launches, labeling content, and conditions of use before they can more fully assess its impact on consumers.

In the United States, sunscreen products are regulated as OTC drugs because their claims involve preventing sunburn and are related to reducing the risk of ultraviolet-related skin damage. This also means that adding a sunscreen ingredient is not merely an adjustment to cosmetic formulation, but requires safety and effectiveness judgments under a drug regulatory framework.

The addition of bemotrizinol may give U.S. sunscreen product developers more formulation options, particularly when seeking a balance among broad-spectrum protection, texture, stability, and consumer acceptance. For brands that have used newer ultraviolet absorbers in other markets, the ingredient list in the U.S. market has historically been relatively conservative, and this update may have demonstrative significance.

But this does not mean that all products containing bemotrizinol will immediately appear on shelves. Manufacturers must still complete formulation, manufacturing, labeling, and launch arrangements in accordance with OTC sunscreen product requirements; the SPF, broad-spectrum labeling, water resistance, and directions for use of different products will also still depend on the test results for each individual product.

From a public health perspective, more compliant sunscreen ingredients help expand the design space for products, but sunscreen remains only one part of ultraviolet protection. This regulatory decision itself does not change general principles for sunscreen use, nor should it be interpreted as a clinical conclusion that a single ingredient is superior to all existing ingredients.

What is relatively certain for now is that the FDA’s inclusion of bemotrizinol as an OTC sunscreen active ingredient marks a new point in U.S. sunscreen regulation after a long period of stagnation. Its subsequent impact will depend on the speed of industry adoption, actual product performance, and whether consumers can access new formulations that are reasonably priced and clearly labeled.